Elevation Oncology, Inc.

Equities

ELEV

US28623U1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:29:52 30/05/2024 am IST			5-day change	1st Jan Change
3.96 ^USD	+3.39%		+3.94%	+637.43%

14/05	Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	MT
02/05	Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Elevation Oncology, Inc. Appoints David Dornan as Chief Scientific Officer

May 05, 2022 at 05:00 pm IST

Elevation Oncology, Inc. announced that David Dornan, appointed Chief Scientific Officer, bringing deep oncology R&D and drug development expertise to further Company's continued focus on future pipeline expansion throughout 2022 and beyond.

Latest news about Elevation Oncology, Inc.

Stephens Starts Elevation Oncology With Overweight Rating, $8 Price Target	14/05	MT
Elevation Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05	CI
Elevation Oncology, Inc. Announces Management Changes	06/04	CI
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan	28/03	MT
Wedbush Raises Elevation Oncology's PT to $8 From $5, Continues to See 'Intriguing' Opportunity in Shares; Keeps Outperform Rating	07/03	MT
Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03	CI
Elevation Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Elevation Oncology, Inc. Appoints Julie Cherrington and Alan Sandler to Board of Directors	04/03	CI
JMP Securities Starts Elevation Oncology' With Market Outperform Rating	01/03	MT
Elevation Oncology Expands Phase 1 Study of Potential Solid Tumor Treatment	22/02	MT
Elevation Oncology Expands Ongoing Phase 1 Clinical Trial of EO-3021 Globally, Dosing First Patient in Japan	22/02	CI
HC Wainwright Adjusts Elevation Oncology Price Target to $6 From $1.50, Maintains Buy Rating	20/02	MT
Elevation Oncology Announces Appointment of Darcy Mootz to Its Board of Directors and as Member of the Compensation Committee	22/01	CI
Elevation Oncology Says It Has Funds to Continue Operations Into H2 2025	06/01	MT
Elevation Oncology, Inc. Plans to Provide an Update from Its Ongoing Phase 1 Trial of EO-3021	05/01	CI
Elevation Oncology, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	02/11	CI
Certain Restricted Stock Units of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Certain Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Certain Pre-funded Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Certain Common Stock of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 7-SEP-2023.	07/23/07	CI
Elevation Oncology, Inc. Announces First Patient Dosed in the Phase 1 Clinical Trial Evaluating E)-3021	16/23/16	CI
Certain Restricted Stock Units of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Certain Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Certain Pre-funded Warrants of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI
Certain Common Stock of Elevation Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-AUG-2023.	08/23/08	CI

Chart Elevation Oncology, Inc.

Duration

Period

More charts

Company Profile

Elevation Oncology, Inc. is an oncology company. The Company is focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. Its lead product candidate, EO-3021 is an antibody-drug conjugate (ADC) designed to target Claudin 18.2, which can selectively deliver a cytotoxic payload directly to cancer cells expressing Claudin 18.2. EO-3021 consists of a fully human immunoglobulin G1 (IgG1) mAb that targets Claudin 18.2 and is site-specifically conjugated to the monomethyl auristatin E (MMAE) payload via a cleavable linker with a drug-to-antibody ratio (DAR) of 2. EO-3021 is designed to bind to Claudin 18.2 on the cell surface and is internalized, upon which the linker is cleaved in the lysosome to release the MMAE payload, a potent anti-mitotic agent. Its second program is an ADC designed to target HER3, which is overexpressed across solid tumors.

Sector

Biotechnology & Medical Research

Calendar

13/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.97 USD

Average target price

7.8 USD

Spread / Average Target

+96.47%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ELEVATION ONCOLOGY, INC.	+637.43%	217M
VERTEX PHARMACEUTICALS INCORPORATED	+8.38%	114B
REGENERON PHARMACEUTICALS, INC.	+10.13%	104B
BIONTECH SE	-11.69%	22.5B
ARGENX SE	+2.21%	22.57B
GENMAB A/S	-10.88%	17.95B
WUXI APPTEC CO., LTD.	-41.90%	16.48B
BEIGENE, LTD.	-16.00%	15.82B
NEUROCRINE BIOSCIENCES, INC.	+2.28%	13.55B
SAREPTA THERAPEUTICS, INC.	+20.54%	10.99B

Bio Therapeutic Drugs